Sagimet Biosciences (SGMT) Competitors $3.68 +0.03 (+0.82%) Closing price 03/7/2025 04:00 PM EasternExtended Trading$3.62 -0.06 (-1.49%) As of 03/7/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SGMT vs. ARCT, STOK, ALLO, UPB, SNDL, PROK, KROS, ALT, CMRX, and CMPXShould you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include Arcturus Therapeutics (ARCT), Stoke Therapeutics (STOK), Allogene Therapeutics (ALLO), Upstream Bio (UPB), SNDL (SNDL), ProKidney (PROK), Keros Therapeutics (KROS), Altimmune (ALT), Chimerix (CMRX), and Compass Therapeutics (CMPX). These companies are all part of the "pharmaceutical products" industry. Sagimet Biosciences vs. Arcturus Therapeutics Stoke Therapeutics Allogene Therapeutics Upstream Bio SNDL ProKidney Keros Therapeutics Altimmune Chimerix Compass Therapeutics Sagimet Biosciences (NASDAQ:SGMT) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, community ranking, valuation, institutional ownership, media sentiment, profitability and dividends. Do analysts prefer SGMT or ARCT? Sagimet Biosciences currently has a consensus target price of $23.00, indicating a potential upside of 525.00%. Arcturus Therapeutics has a consensus target price of $61.40, indicating a potential upside of 321.99%. Given Sagimet Biosciences' higher possible upside, equities research analysts clearly believe Sagimet Biosciences is more favorable than Arcturus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sagimet Biosciences 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has more volatility and risk, SGMT or ARCT? Sagimet Biosciences has a beta of 2.57, suggesting that its share price is 157% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.96, suggesting that its share price is 196% more volatile than the S&P 500. Is SGMT or ARCT more profitable? Sagimet Biosciences has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -36.39%. Arcturus Therapeutics' return on equity of -22.39% beat Sagimet Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Sagimet BiosciencesN/A -23.63% -22.91% Arcturus Therapeutics -36.39%-22.39%-14.81% Does the MarketBeat Community believe in SGMT or ARCT? Arcturus Therapeutics received 419 more outperform votes than Sagimet Biosciences when rated by MarketBeat users. However, 96.30% of users gave Sagimet Biosciences an outperform vote while only 66.32% of users gave Arcturus Therapeutics an outperform vote. CompanyUnderperformOutperformSagimet BiosciencesOutperform Votes2696.30% Underperform Votes13.70%Arcturus TherapeuticsOutperform Votes44566.32% Underperform Votes22633.68% Which has stronger valuation & earnings, SGMT or ARCT? Sagimet Biosciences has higher earnings, but lower revenue than Arcturus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSagimet Biosciences$2M56.44-$27.88MN/AN/AArcturus Therapeutics$138.39M2.85-$29.73M-$3.01-4.83 Does the media refer more to SGMT or ARCT? In the previous week, Arcturus Therapeutics had 13 more articles in the media than Sagimet Biosciences. MarketBeat recorded 14 mentions for Arcturus Therapeutics and 1 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.00 beat Arcturus Therapeutics' score of -0.41 indicating that Sagimet Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcturus Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of SGMT or ARCT? 87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 17.6% of Sagimet Biosciences shares are held by insiders. Comparatively, 15.3% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryArcturus Therapeutics beats Sagimet Biosciences on 10 of the 17 factors compared between the two stocks. Remove Ads Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SGMT vs. The Competition Export to ExcelMetricSagimet BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$112.88M$7.31B$5.86B$8.33BDividend YieldN/A2.77%4.89%4.02%P/E RatioN/A6.2625.0819.35Price / Sales56.44225.04377.99118.00Price / CashN/A65.6738.1234.62Price / Book0.926.517.304.23Net Income-$27.88M$140.25M$3.19B$247.13M7 Day Performance-0.81%-2.36%-1.62%-2.37%1 Month Performance-19.47%-3.89%-3.73%-6.13%1 Year Performance-36.00%-10.63%12.86%2.84% Sagimet Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SGMTSagimet Biosciences2.4711 of 5 stars$3.68+0.8%$23.00+525.0%-42.9%$112.88M$2M0.008Positive NewsARCTArcturus Therapeutics2.3823 of 5 stars$16.69-6.1%$65.00+289.5%-60.9%$452.08M$142.47M-7.52180Earnings ReportAnalyst ForecastNews CoverageGap DownSTOKStoke Therapeutics3.7301 of 5 stars$8.50+2.0%$23.00+170.6%+4.7%$450.22M$16.74M-4.05100Positive NewsALLOAllogene Therapeutics2.5713 of 5 stars$2.14-1.4%$9.73+354.8%-60.9%$448.69M$90,000.00-1.37310Upcoming EarningsUPBUpstream BioN/A$8.22+3.0%$56.50+587.3%N/A$440.57M$2.21M0.0038Upcoming EarningsNews CoverageSNDLSNDL3.5725 of 5 stars$1.67-5.6%$3.25+94.6%+17.3%$438.84M$673.33M-5.392,516News CoveragePROKProKidney1.5805 of 5 stars$1.50flat$4.50+200.0%-36.7%$437.49MN/A-2.733KROSKeros Therapeutics3.4923 of 5 stars$10.79-2.1%$52.56+387.1%-83.7%$437.10M$150,000.00-2.07100ALTAltimmune2.3009 of 5 stars$6.11-5.0%$20.83+241.0%-44.5%$434.54M$430,000.00-3.9450Analyst RevisionNews CoverageCMRXChimerix2.7132 of 5 stars$4.76-7.6%$9.00+89.1%+569.0%$428.10M$159,000.00-5.0690Analyst ForecastNews CoverageCMPXCompass Therapeutics3.5343 of 5 stars$3.11+6.5%$11.38+265.8%+40.1%$427.91MN/A-8.4120Short Interest ↑ Remove Ads Related Companies and Tools Related Companies Arcturus Therapeutics Competitors Stoke Therapeutics Competitors Allogene Therapeutics Competitors Upstream Bio Competitors SNDL Competitors ProKidney Competitors Keros Therapeutics Competitors Altimmune Competitors Chimerix Competitors Compass Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SGMT) was last updated on 3/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored[BREAKING NOW] Gold Is Literally Moving—And So Is Its PriceFor decades, I’ve accurately predicted every major gold move—because the signs were always there. Now, I’m ...Golden Portfolio | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sagimet Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SGMT Stock Alerts